Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. News
Aurinia Pharmaceuticals Inc. Quantitative Score
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Aurinia Pharmaceuticals Inc. Financials
Table Compare
Compare AUPH metrics with: | |||
|---|---|---|---|
Earnings & Growth | AUPH | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AUPH | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AUPH | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AUPH | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Aurinia Pharmaceuticals Inc. Income
Aurinia Pharmaceuticals Inc. Balance Sheet
Aurinia Pharmaceuticals Inc. Cash Flow
Aurinia Pharmaceuticals Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Aurinia Pharmaceuticals Inc. Executives
| Name | Role |
|---|---|
| Mr. Peter S. Greenleaf M.B.A. | President, Chief Executive Officer & Director |
| Mr. Matthew Maxwell Donley M.B.A. | Chief Operations Officer |
| Mr. Joseph M. Miller CPA | Chief Financial Officer |
| Mr. Stephen P. Robertson | Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Peter S. Greenleaf M.B.A. | President, Chief Executive Officer & Director | Male | 1970 | 1.59M |
| Mr. Matthew Maxwell Donley M.B.A. | Chief Operations Officer | Male | 1969 | 933.95K |
| Mr. Joseph M. Miller CPA | Chief Financial Officer | Male | 1974 | 866.87K |
| Mr. Stephen P. Robertson | Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer | Male | 1982 | 799.52K |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer | 1961 | 779.11K |
Aurinia Pharmaceuticals Inc. Insider Trades
| Date | 16 May |
| Name | Nova Tina Susan |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 63724 |
| Date | 16 May |
| Name | Johnson Craig A |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 37485 |
| Date | 16 May |
| Name | Goetz Kathleen |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 63724 |
| Date | 16 May |
| Name | Bailey Jeffrey Allen |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 37485 |
| Date | 15 May |
| Name | Nova Tina Susan |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 16 May | Nova Tina Susan | Director | Acquired | A-Award | 63724 |
| 16 May | Johnson Craig A | Director | Acquired | A-Award | 37485 |
| 16 May | Goetz Kathleen | Director | Acquired | A-Award | 63724 |
| 16 May | Bailey Jeffrey Allen | Director | Acquired | A-Award | 37485 |
| 15 May | Nova Tina Susan | Director | Disposed | 0 |